文献速递外周动脉疾病

冷冻保存大隐静脉作为下肢血运重建的最后选择

Cryopreserved saphenous vein as a last-ditch conduit for limb salvage.
PubMed 文献 · J Vasc Surg · 2017-05-11

本研究回顾性分析了70例缺乏自体静脉的患者使用冷冻保存大隐静脉(CSV)进行腹股沟下旁路移植的结局。主要结论为:在多学科团队和积极伤口护理下,CSV可作为缺血性组织丢失且无自体导管的患者的合理选择,但中远期通畅率不佳,需优化患者选择。

要点

  • CSV用于无自体静脉的腹股沟下旁路,1年一期通畅率仅35%。
  • 30天失败与ABO血型不匹配及供体B或AB型血相关。
  • 多变量分析中,非黑人种族、供体B或AB型血、胫或足部靶血管与一期通畅率丧失独立相关。

核心结论

  • 在多学科团队和积极伤口护理下,CSV可作为缺血性组织丢失且缺乏自体导管的患者腹股沟下血运重建的合理选择。
  • 但中远期通畅率不佳,需优化患者选择以获得有意义的临床获益。

研究设计与样本

  • 回顾性研究,2008年2月至2015年8月,70例患者共73条肢体使用CSV行腹股沟下旁路移植。
  • 所有患者均缺乏合适的手臂或腿部静脉。
  • 通过电子病历回顾性收集人口学数据和患者结局。

主要发现

  • 队列平均年龄70±14岁,男性36例(51%);白人47例(67%),冠心病39例(56%),糖尿病27例(39%),高血压56例(80%),吸烟者50例(71%)。
  • 中位随访304天(四分位距130-991天)。
  • 手术指征包括静息痛(27%)、组织丢失(55%)和人工血管感染(18%);62/73(85%)旁路用于严重肢体缺血,45/73(62%)为再次手术。
  • 远端靶血管包括股浅动脉或腘动脉(38%)、胫动脉(55%)和足部动脉(7%);所有移植物最小直径3 mm。
  • 30天时,64例中有55例(86%)移植物通畅,9例早期失访。

关键数值与推荐

  • 30天失败的唯一显著危险因素为ABO血型不匹配(43% vs 10%;P = .05)和供体B或AB型血(40% vs 9%;P = .03)。
  • 估计总体1年一期通畅率为35%。
  • 多变量分析中,非黑人种族(P = .05)、供体B或AB型血(P = .01)和旁路至胫或足部靶血管(P = .05)与一期通畅率丧失独立相关。
  • 共有20例(27%) major截肢,这些肢体的所有移植物在截肢时均已闭塞。
  • 在有长期随访的33条缺血性组织丢失肢体中,17/33(52%)发生移植物闭塞,10/33(30%)行major截肢,24/33(73%)原发伤口完全愈合。

临床怎么用

  • 对于缺乏自体静脉的腹股沟下血运重建患者,CSV可作为一种选择,但需在多学科团队和积极伤口护理下使用。
  • 应避免ABO血型不匹配和供体B或AB型血,以降低早期失败风险。
  • 旁路至胫或足部靶血管时需谨慎评估,因与一期通畅率丧失独立相关。

局限性

  • 回顾性研究设计。
  • 样本量较小(70例患者,73条肢体)。
  • 中位随访时间较短(304天),部分患者失访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In patients lacking autogenous vein suitable for infrainguinal bypass, cryopreserved saphenous vein (CSV) allograft (CryoLife, Inc, Kennesaw, Ga) may be an acceptable alternative. The purpose of this study was to examine outcomes of CSV conduit for infrainguinal revascularization. METHODS: Between February 2008 and August 2015, 70 patients underwent infrainguinal bypass grafts in 73 limbs using CSV. All patients lacked suitable arm or leg vein. Demographic data and patient outcomes were retrospectively collected using electronic medical records. RESULTS: The mean age of our cohort was 70 ± 14 years, and 36 (51%) were male; 47 (67%) were white, 39 (56%) had coronary artery disease, 27 (39%) had diabetes, 56 (80%) had hypertension, and 50 (71%) were former or current smokers. Median follow-up was 304 days (interquartile range, 130-991 days). Indications for the index operation included rest pain (27%), tissue loss (55%), and prosthetic graft infection (18%); 62 of 73 (85%) bypasses were performed for critical limb ischemia, and 45 of 73 (62%) were redo operations. Distal targets included superficial femoral artery or popliteal (38%), tibial (55%), and pedal (7%). All grafts had a minimum diameter of 3 mm. At 30 days, 55 of 64 grafts (86%) were patent; 9 were lost to early follow-up. The only significant risk factors associated with 30-day failure were ABO mismatch (43% vs 10%; P = .05) and donor blood type B or AB (40% vs 9%; P = .03). Estimated overall 1-year primary patency was 35%. In a multivariate analysis, nonblack race (P = .05), donor B or AB blood type (P = .01), and bypass to a tibial or pedal target (P = .05) were independently associated with loss of primary patency. There were 20 (27%) major amputations, and all grafts in these limbs had occluded at the time of amputation. Of the 33 limbs with ischemic tissue loss that had long-term follow-up, 17 of 33 (52%) went on to graft occlusion, 10 of 33 (30%) had a major amputation, and 24 of 33 (73%) had complete healing of the index wound. CONCLUSIONS: In the setting of a multidisciplinary team with aggressive wound care, CSV may be a reasonable choice for infrainguinal revascularization in patients with ischemic tissue loss who lack autogenous conduit. However, poor midterm to long-term patency suggests that optimal selection of patients is needed to derive meaningful clinical benefit.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. O'Banion LA, Wu B, Eichler CM, et al. Cryopreserved saphenous vein as a last-ditch conduit for limb salvage. J Vasc Surg. 2017. PMID: 28502546. doi:10.1016/j.jvs.2017.03.415

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。